On May 3, 2019, Health Canada released the new Guidance Document: Regulatory requirements for Drug Identification Numbers (DINs). The Guidance Document is stated to provide “assistance on the interpretation of the regulatory requirements associated with a DIN” and “guidance to manufacturers on their obligation to accurately report to Health Canada [certain] notifications for a change of drug status.” This Guidance Document replaces a number of Health Canada documents including:
- Guidance Document: Cancellation of a Drug Identification Number (DIN) and Notification of Discontinuation of Sales
- Issuance of Drug Identification Numbers for New Drugs
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More